Recent studies have explored the potential of thyroid hormone receptor-beta agonists as therapeutic agents for MASLD, aiming to harness the metabolic regulatory functions of thyroid hormones to ameliorate liver steatosis and inflammation. Here, TG is linked to Hepatic steatosis.